Alan H. Beggs

Alan H. Beggs, PhD, is the Director of the Manton Center for Orphan Disease Research at Boston Children's Hospital and holds the Sir Edwin & Lady Manton Professorship of Pediatrics at Harvard Medical School. His laboratory, within the Division of Genetics and Genomics, focuses on gene discovery, genomic diagnostics, and therapeutic development for rare neuromuscular disorders, particularly congenital myopathies such as nemaline and myotubular myopathy.

Dr. Beggs earned his PhD in Human Genetics from Johns Hopkins University and completed postdoctoral training at Johns Hopkins and Boston Children’s Hospitals. His research leverages genomic approaches in human patients and animal models to understand disease mechanisms and develop targeted therapies. He has contributed to the discovery of over a dozen disease genes and maintains one of the largest patient data and specimen banks for congenital myopathy.

His research interests span Genetics and Genomics, Rare Genetic Diseases, Neuromuscular Disorders, Gene Discovery, Genomic Diagnostics, Animal Models, and Gene Therapy. His recent publications highlight advancements in zebrafish modeling, long-read sequencing, genotype-phenotype correlations, and gene therapy for rare pediatric conditions. Trends in his work emphasize precision diagnostics, translational research, and the development of novel therapeutic strategies for devastating childhood disorders.

Dr. Beggs is actively involved in major research initiatives such as the BabySeq Project and the International Precision Child Health Partnership (IPCHiP), which aim to improve outcomes through newborn genomic sequencing and global collaboration. He has collaborated with experts in muscle mechanics and pharmacology to test drugs and gene therapies, resulting in patents and the formation of biotechnology companies planning clinical trials.

His laboratory serves as a training ground for researchers in genetics and has contributed significantly to the field through extensive publication in top-tier journals and leadership in rare disease research infrastructure.